Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype. The main features of TNBC are lack of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor 2 receptors (HER2) [1]. Chemotherapy is the main treatment strategy for TNBC patients. However, severe side effects and unpredictable treatment efficacy remain the main concern of chemotherapy [2]. In recent years it has been shown that many different microRNAs (miRNAs) are frequently dysregulated and can be secreted into the circulatory system. For the following reasons, miRNAs in urine could serve as a promising tool for identifying non-invasive biomarkers for TNBC [3].
The aim of this research was to identify dysregulated miRNAs which are associated with chemoresistance in TNBC and could help to predict the response to treatment.
To evaluate miRNAs abundance differences in serial urine specimens, we used quantitative reverse transcription PCR (RT-qPCR). In our going research, in more than 50 serial TNBC samples 4 miRNAs expression was examined (miR-200a, miR-210, miR-125a, miR-454). The samples were collected before and 6 months after the treatment of paclitaxel combined with carboplatin, or 4 cycles of doxorubicin combined with cyclophosphamide. Comparative analysis showed that all miRNAs were upregulated, however, not all of them showed significant differences comparing before and after treatment groups. This suggests our analyzed miRNAs involvement in response to chemotherapy treatment and that urine could be used as a completely non-invasive tool for TNBC treatment monitoring.
Overall, miRNA-200a, miRNA-210, miRNA-125a and miRNA-454 are involved in resistance to chemotherapy mechanisms. Identification of these miRNAs level differences in TNBC patients' urine specimens could be used as a completely non-invasive method which would help to predict the efficacy of treatment.